Researchers in the United States (US) have developed 3D printed micro-needles, which will be able to administer the medicinal drugs in the human body without any pain to the patient.
For years, we’ve been told to break habits that hurt our skin (i.e. don’t pick at scabs) but could we be doing it wrong? Could hurting our skin actually make it look better? Many plastic surgeons and dermatologists say yes. RealSelf asked 500 board-certified doctors to predict the hot aesthetic trend for 2016. The answer that came up most often? Microneedling.
Eli Lilly ($LLY) is upsizing its New York City R&D outpost, planning to add 50 new jobs and take up more lab space with a particular focus on immuno-oncology.
Team Leuko, an international group collaborating between the Massachusetts Institute of Technology (MIT) and a handful of centers, hospitals, and foundations primarily located in Madrid, Spain, has developed a device that counts patients’ white blood cells in real-time through the skin (i.e., without drawing blood). With the use of this device, patients undergoing chemotherapy will be able to track their immune behavior responsively, much as diabetics can quickly gauge and react to their blood glucose levels.
Dick Crawford, an engineer and entrepreneur who is chair, co-founder and CEO of PKA SoftTouch Corp. in Lakefield says his development team has been working on the microneedle for nine years.
Dissolving ‘microneedles’ could make injections much safer and cheaper to provide in poor countries, as well as helping people who are afraid of injections
Transdermal delivery via microneedles is increasingly gaining traction as one of the more promising drug delivery technologies. Microneedles are of a few hundred microns in size, capable of creating transient pores across the skin by penetrating the stratum corneum layer to deliver molecules. These needles are not big enough to reach the nerve-rich regions of the skin; as a result, the drug delivery is perceived as completely painless and devoid of bleeding. Drugs, vaccines, proteins, peptides and other biomolecules are suitable for delivery using the microneedle technology.
Needle-free drug delivery technologies are used to deliver drugs or vaccines into a patient’s body without the need for a traditional needle. The primary objectives of the development of these technologies are to eliminate NSI and its associated complications and increase patient compliance and comfort. Needle-free drug delivery systems include jet injectors, microneedles, nanopatches, and vaccine implants. The advantages of these systems over conventional syringes are expanded immunization coverage, decreased healthcare costs, and increased patient compliance.
J&J may not be in the front ranks of the immuno-oncology giants, but it is carving out a place for itself in the hottest field in biopharma R&D. J&J's ($JNJ) research unit Janssen has inked back-to-back I/O deals with two small biotechs in the U.S. and Europe.
A comparison of two methods for delivering influenza vaccines has concluded that dissolvable microneedles perform at least as well as the traditional hypodermic. Microneedle patches could have advantages both in delivering vaccines to remote locations and in overcoming resistance to vaccination. Microneedles replace a single large needle with numerous needles so small they can barely be seen or felt, each delivering a fraction of the dose required to induce an immune response in the patient.
Pricking your finger and meticulously checking your blood sugar could no longer be the only way people with diabetes handle the disease. Researches from the University of North Carolina at Chapel Hill and N.C. State University are working to replace this painful process with a thin square patch the size of a penny. It is a “smart insulin patch” that can detect increases in blood sugar levels. The patch has more than a hundred tiny microneedles, each about the size of an eyelash.
OND are developing novel techniques and materials to produce low cost needle patches to deliver vaccines and drugs to the immune system http://www.oxfordnanodelivery.com
Chinese cancer immunotherapy player BeiGene just filed a $100 IPO with the U.S. Securities Exchange Commission to advance its clinical pipeline of BTK, RAF and PARP inhibitors.
Photodynamic therapy involves delivery of a photosensitising drug that is activated by light of a specific wavelength, resulting in generation of highly reactive radicals. This activated species can cause destruction of targeted cells. Application of this process for treatment of microbial infections has been termed "photodynamic antimicrobial chemotherapy" (PACT).
Scientists from the University of Akron and University of Texas today announced a pioneering technique for producing 3D micro-printed needles. The needles, measuring no more than 1 mm high, are made from a biomaterial that after painlessly delivering the drug would simply degrade into the patient’s body. They could be used to treat a wide range of diseases including skin cancer and help reduce the stigma associated with injections.
The aim of this project was to study the influence of microneedles on transdermal delivery of amantadine hydrochloride and pramipexole dihydrochloride across porcine ear skin in vitro. Microchannel visualization studies were carried out and characterization of the microchannel depth was performed using confocal laser scanning microscopy (CLSM) to demonstrate microchannel formation following microneedle roller application. We also report, for the first time, the use of TA.XT Plus Texture Analyzer to characterize burst force in pig skin for transdermal drug delivery experiments. This is the force required to rupture pig skin.
Microscale needle-electrode array technology has been enhancing brain sciences and engineering such as electrophysiological studies, drug and chemical delivery systems, and optogenetic applications. However, one challenge is reducing the tissue/neuron damage associated with needle penetration, particularly for chronic studies and future medical applications. A way to solve the issue is to use microscale diameter needles (e.g., < 5 microns) along with a flexible property, but such physically poor needles cannot penetrate into the brain and other biological tissues due to needle buckling or fracturing before penetration.
NanoPass Technologies Ltd. ("NanoPass"), a pioneer in intradermal delivery solutions for immunotherapies, announced today that it has entered into a clinical supply and support agreement for the supply of MicronJet600™, its microneedle delivery device, for use with Immune Design's oncology immunotherapy products from its ZVex[TM] discovery platform. The agreement will provide Immune Design non-exclusive access and supply for use of the device in all of its relevant cancer immunotherapy programs globally. Financial terms were not disclosed.
The flu vaccine used in the study is the same as the FDA-approved flu vaccine from last season. The purpose of the study is to assess the safety of the microneedle patch, how the body's immune system responds to the vaccine delivered through a patch, and participants' opinions about using the patch. Participants will receive follow up, including blood work, during six visits over six months.
Transdermal delivery via microneedles is increasingly gaining traction as one of the more promising drug delivery technologies. Microneedles are of a few hundred microns in size, capable of creating transient pores across the skin by penetrating the stratum corneum layer to deliver molecules. These needles are not big enough to reach the nerve-rich regions of the skin; as a result, the drug delivery is perceived as completely painless and devoid of bleeding. Drugs, vaccines, proteins, peptides and other biomolecules are suitable for delivery using the microneedle technology.
This study establishes a proof-of-concept that a tattoo device can target intra-dermal drug delivery against cutaneous leishmaniasis (CL). The selected drug is oleylphosphocholine (OlPC) formulated as liposomes, particles known to be prone to macrophage ingestion. We first show that treatment of cultured Leishmania-infected macrophages with OlPC-liposomes results in a direct dose-dependent killing of intracellular parasites.
In a paper published this month in Biomaterials, scientists from Osaka University describe their successful experimentation with a new inoculation method which utilizes tiny, biodegradable microneedles made of hyaluronic acid, a naturally occurring substance found in your body’s joints. Those microneedles sit on a coin-sized patch which a patient simply affixes to their arm, allowing the tips of the needles to pass through just the very top dermal layers. As medicine flows through the patch and into you, the needles themselves begin to disintegrate from the moisture in your skin. The patch, dubbed “MicroHyala,” is easy to apply, and requires no extensive medical training, which makes it perfect for use by aid workers in remote, or developing locales in which trained professional physicians may be scarce.
One hundred sixty years after the invention of the needle and syringe, we're still using them to deliver vaccines; it's time to evolve. Biomedical engineer Mark Kendall demos the Nanopatch, a one-centimeter-by-one-centimeter square vaccine that can be applied painlessly to the skin. He shows how this tiny piece of silicon can overcome four major shortcomings of the modern needle and syringe, at a fraction of the cost.
To get content containing either thought or leadership enter:
To get content containing both thought and leadership enter:
To get content containing the expression thought leadership enter:
You can enter several keywords and you can refine them whenever you want. Our suggestion engine uses more signals but entering a few keywords here will rapidly give you great content to curate.
Your new post is loading...
Scoop.it!
